Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Dendreon DOA in Europe?

By Dave Williamson - Nov 21, 2012 at 6:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NASDAQ: MDVN

Medivation, Inc.

Dendreon's drug may have lost the battle for Europe before it even began.

On Monday, Johnson & Johnson (NYSE: JNJ) received approval in Europe for Zytiga as a pre-chemo treatment for prostate cancer. With Dendreon's (NASDAQ: DNDN) drug Provenge not approved in Europe yet, should investors be concerned about its ability to gain traction on the continent? Watch the following video and find out.

Stocks Mentioned

$173.94 (-0.89%) $-1.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

2 Biotech Stocks that Turned $8,000 into over $250,000

Is Pfizer Paying Too Much to Buy Medivation?

What's Up With Mylan's EpiPen Pricing?

3 Stocks Up Over 1,000% in the Past 5 Years

What Pfizer Gets in Its $14 Billion Medivation Deal

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

327%

S&P 500 Returns

116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.